Bioxyne (ASX:BXN) has secured a two-year supply agreement worth up to $50 million with German pharmaceutical company ADREXpharma GmbH, a move the Australian firm says will give it a defined pathway into Europe and near-term revenue visibility.
The deal includes a $25 million minimum purchase commitment in the first 12 months and automatic renewal for a further 12 months.
Under the agreement, Bioxyne’s wholly owned subsidiary, Breathe Life Sciences, will supply Australian GMP-manufactured cannabis flower and other products for onward distribution through ADREXpharma’s established German customer network.
ADREXpharma has been granted exclusive rights to the Dr Watson brand in Germany, supporting targeted market penetration in Europe’s largest medicinal cannabis market.
Sam Watson, Chief Executive Officer of Bioxyne, said the expanded arrangement reflects the company’s momentum in regulated European markets and its broader pharmaceutical ambitions. “This expanded supply agreement with Adrex reflects the scale and momentum we are building in new markets and strengthens our position across key regulated European markets as we continue to grow our broader pharmaceutical portfolio. While cannabis remains the largest commercial part of Bioxyne’s business today, we are actively progressing opportunities to expand into additional medicines and controlled substances with both established and emerging therapeutic applications. Adrex’s strong presence and expertise in European pharmaceutical markets makes them a natural partner as we look to expand into new therapeutic areas.”
Nicole Broockmann, Chief Executive Officer of ADREXpharma, said the companies have spent the past six months refining product quality and supply chain operations, and that the agreement positions them to scale in Germany’s expanding market.
“Over the past six months, we have built a strong foundation together with Bioxyne and BLS, refining product quality, strengthening the supply chain, and establishing the operational framework required to support long-term growth in Germany. This agreement positions both companies to build a scalable platform capable of becoming a significant supplier into Germany’s rapidly expanding medicinal cannabis market, which is now estimated at more than 200 tonnes per annum. Bioxyne’s GMP manufacturing capability, combined with our local distribution expertise and pharmacy network, creates a strong partnership to meet increasing patient demand across the market.”
The expanded contract is described by Bioxyne as a material expansion of an initial supply arrangement signed in June 2025 and aligns with the company’s strategy to scale GMP-certified manufacturing and supply across regulated international markets.